Cohort 9 Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no dose limiting toxicities (DLTs) or…
VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end…
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the…
Key apps from the iCAD Breast Health Suite are now integrated with GE HealthCare’s new MyBreastAI Suite*AI applications streamline workflow…
NEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company…
Upgrade of Gamma Knife® 4C with NEW Elekta ICON for most precise and accurate treatment of Intracranial cancers and other…
Gained alignment with global health authorities for pivotal Phase 3 SEACRAFT-2 trial design for naporafenib plus trametinib in NRAS mutant…
Designation is for 2nd or 3rd line treatment of patients with disease progression following treatment with endocrine therapy and a…
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing…
PRINCETON, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage…